Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update
NUCLEAR MEDICINE COMMUNICATIONS, vol.39, no.8, pp.789-796, 2018 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 39 Issue: 8
- Publication Date: 2018
- Doi Number: 10.1097/mnm.0000000000000874
- Journal Name: NUCLEAR MEDICINE COMMUNICATIONS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.789-796
- Keywords: Lu-177-DOTATATE, neuroendocrine tumours, octreotide, peptide receptor radionuclide therapy, radionuclide therapy, somatostatin, RECEPTOR RADIONUCLIDE THERAPY, PHASE-II, MIDGUT, NEOPLASMS, CARCINOMAS, OCTREOTIDE, EXPRESSION, TOXICITY, EFFICACY, TRIAL
- Istanbul University Affiliated: Yes
Abstract
Purpose Upon diagnosis, distant metastases are encountered in 21-50% of neuroendocrine tumours (NETs). However, few systemic treatment options are available for the well-differentiated NETs in the metastatic stage. Lu-177-DOTATATE is one of the most effective treatments in this limited patient group. We retrospectively investigated its efficacy and effect on the survival in patients with both well-differentiated and grade III NETs who had high uptake in pretherapeutic Ga-68-DOTATATE PET/computed tomography scans.